Syros Pharmaceuticals (SYRS) Tops Q4 EPS by 1c

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q4 EPS of ($0.46), $0.01 better than the analyst estimate of ($0.47).

“We are entering 2020 in a position of strength,” said Nancy Simonian, M.D., Chief Executive Officer of Syros. “Following the recent initiation of our Phase 1 trial of SY-5609, we are advancing two oral investigational medicines through development in multiple cancer patient populations that we believe are most likely to respond to these targeted agents, both with meaningful data readouts expected in the fourth quarter. Meanwhile, our gene control platform continues to fuel a robust preclinical and discovery pipeline in oncology and monogenic diseases. We are committed to executing with excellence on our ongoing efforts and, longer term, to leveraging our deep understanding of the regulatory genome to deliver much-needed medicines that provide profound benefits for patients.”

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Nanometrics (NANO) Issues Business Update, Reports FY23 Results
• WM (WM) Tops Q1 EPS by 25c
• Plexus Corp (PLXS) Tops Q2 EPS by 7c